首页 > 最新文献

Digestive Diseases and Sciences最新文献

英文 中文
Yield of Gluten Challenge in Patients on Self-Prescribed Gluten-Free Diets. 自配无麸质饮食患者的麸质挑战产量。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-05-20 DOI: 10.1007/s10620-024-08399-5
Martin Ventoso, John Henry Ignatiev, Seokyu Shin, Suneeta Krishnareddy, Suzanne Lewis, Peter H R Green, Benjamin Lebwohl

Background: Patients on a gluten-free diet (GFD) whose celiac disease (CD) status is unknown may undergo gluten challenge (GC) to clarify their diagnosis. Though this is an established diagnostic practice, the proportion of patients undergoing GC who are diagnosed with CD is unknown.

Aims: We aimed to analyze which factors were predictive of having CD in a cohort of patients who underwent GC followed by upper endoscopy with duodenal biopsy.

Methods: We identified adult patients at a CD referral center who had been on a GFD and then underwent GC to determine a diagnosis of CD during the years spanning 2006 to 2020. We compared those patients found to have CD (defined as villus atrophy/Marsh 3) on duodenal biopsy with those who did not, using the chi square and Fischer exact tests.

Results: We identified 206 patients who underwent GC. Of these 206, 30 (14%) were diagnosed with CD based on post-GC duodenal biopsy. 176 of the 206 (85%) patients reported various gastrointestinal symptoms, including bloating (39%), though these were more common in those without CD (any GI symptoms: 89% vs 67%, p 0.004; bloating: 43% vs 20%, p 0.019). Serology values, when normalized, including pre- and post-challenge TTG IgA (37% vs 1.7%, p 0.001; 23% versus 2.3%, p 0.001), DGP IgG and IgA (57% vs 2.8%, p 0.001; 37% vs 6.2%, p 0.001) were higher in the group of patients with CD.

Conclusion: Among patients undergoing GC for diagnostic purposes, only 14% had evidence of villus atrophy corresponding with CD on duodenal biopsy. The presence of any elevated pre-challenge serology was associated with CD. Bloating in combination with low serologies may help risk stratify patients as being less likely to have CD upon GC.

背景:接受无麸质饮食(GFD)但乳糜泻(CD)状态不明的患者可能会接受麸质挑战(GC)以明确诊断。目的:我们旨在分析在接受麸质挑战(GC)后进行上内镜检查和十二指肠活检的患者队列中,哪些因素可预测患者是否患有乳糜泻:我们在一家 CD 转诊中心找到了 2006 年至 2020 年期间曾服用 GFD 并接受 GC 检查以确定 CD 诊断的成年患者。我们使用秩方检验(chi square)和费舍尔精确检验(Fischer exact tests)对十二指肠活检发现患有 CD(定义为绒毛萎缩/Marsh 3)的患者与未患有 CD 的患者进行了比较:我们确定了 206 名接受 GC 检查的患者。结果:我们确定了 206 名接受 GC 的患者,其中 30 人(14%)根据 GC 后十二指肠活检确诊为 CD。206 名患者中有 176 名(85%)报告了各种胃肠道症状,包括腹胀(39%),但这些症状在无 CD 的患者中更为常见(任何胃肠道症状:89% 对 67%,P 0.004;腹胀:43% 对 20%,P 0.019)。血清学值正常化后,包括挑战前和挑战后的 TTG IgA(37% vs 1.7%,P 0.001;23% vs 2.3%,P 0.001)、DGP IgG 和 IgA(57% vs 2.8%,P 0.001;37% vs 6.2%,P 0.001)在 CD 患者组中更高:结论:在接受 GC 诊断的患者中,只有 14% 的患者在十二指肠活检中发现了与 CD 相符的绒毛萎缩证据。任何挑战前血清学升高都与 CD 相关。腹胀与低血清学指标的结合可能有助于对患者进行风险分层,使其在接受 GC 检查时较少可能患有 CD。
{"title":"Yield of Gluten Challenge in Patients on Self-Prescribed Gluten-Free Diets.","authors":"Martin Ventoso, John Henry Ignatiev, Seokyu Shin, Suneeta Krishnareddy, Suzanne Lewis, Peter H R Green, Benjamin Lebwohl","doi":"10.1007/s10620-024-08399-5","DOIUrl":"10.1007/s10620-024-08399-5","url":null,"abstract":"<p><strong>Background: </strong>Patients on a gluten-free diet (GFD) whose celiac disease (CD) status is unknown may undergo gluten challenge (GC) to clarify their diagnosis. Though this is an established diagnostic practice, the proportion of patients undergoing GC who are diagnosed with CD is unknown.</p><p><strong>Aims: </strong>We aimed to analyze which factors were predictive of having CD in a cohort of patients who underwent GC followed by upper endoscopy with duodenal biopsy.</p><p><strong>Methods: </strong>We identified adult patients at a CD referral center who had been on a GFD and then underwent GC to determine a diagnosis of CD during the years spanning 2006 to 2020. We compared those patients found to have CD (defined as villus atrophy/Marsh 3) on duodenal biopsy with those who did not, using the chi square and Fischer exact tests.</p><p><strong>Results: </strong>We identified 206 patients who underwent GC. Of these 206, 30 (14%) were diagnosed with CD based on post-GC duodenal biopsy. 176 of the 206 (85%) patients reported various gastrointestinal symptoms, including bloating (39%), though these were more common in those without CD (any GI symptoms: 89% vs 67%, p 0.004; bloating: 43% vs 20%, p 0.019). Serology values, when normalized, including pre- and post-challenge TTG IgA (37% vs 1.7%, p 0.001; 23% versus 2.3%, p 0.001), DGP IgG and IgA (57% vs 2.8%, p 0.001; 37% vs 6.2%, p 0.001) were higher in the group of patients with CD.</p><p><strong>Conclusion: </strong>Among patients undergoing GC for diagnostic purposes, only 14% had evidence of villus atrophy corresponding with CD on duodenal biopsy. The presence of any elevated pre-challenge serology was associated with CD. Bloating in combination with low serologies may help risk stratify patients as being less likely to have CD upon GC.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic Pancreatitis in a Large Developing Country: Temporal Trends of Over 64,000 Hospitalizations from 2009 to 2019. 一个发展中大国的慢性胰腺炎:2009年至2019年超过64,000例住院治疗的时间趋势。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-05-30 DOI: 10.1007/s10620-024-08488-5
Pedro Baldaque, Gabriela Coutinho, Jessica Pronestino de Lima Moreira, Ronir Raggio Luiz, Homero Soares Fogaça, Lucila Marieta Perrotta de Souza, Heitor Siffert Pereira de Souza

Background/objectives: Chronic pancreatitis (CP) is a progressive inflammatory disorder associated with marked morbidity and mortality and frequently requires hospitalization. This study aimed to investigate the time trends and geographical distribution of hospital admissions, the lethality rate of CP across Brazil, and the potential relationship with social indicators and associated risk factors.

Methods: Data were retrospectively obtained from the Brazilian Public Health System Registry between January 2009 and December 2019. The prevalence and lethality rates of CP per 100,000 inhabitants in each municipality were estimated from hospitalizations to in-hospital deaths and classified by age, sex, and demographic features.

Results: During the study period, 64,609 admissions were retrieved, and most of the patients were males (63.54%). Hospitalization decreased by nearly half (-54.68%) in both sexes. CP rates in males were higher in all age groups. The greatest reduction in admissions (- 64%) was also noted in patients ≥ 70y. CP In-hospital lethality remained stable (5-6%) and similar for males and females. Patients ≥ 70y showed the highest lethality. The greatest increase in CP lethality rates (+ 10%) was observed in municipalities integrated into metropolises, which was mainly driven by small-sized municipalities (+ 124%).

Conclusions: CP hospitalizations decrease in both urban and rural areas, particularly in the North, Northeast, and Central-West regions, and in those above 70 years of age, but are not correlated with lethality rates in the South. This suggests ongoing changes in the environmental and socioeconomic factors in Brazil.

背景/目的:慢性胰腺炎(CP)是一种进行性炎症性疾病,具有明显的发病率和死亡率,经常需要住院治疗。本研究旨在调查慢性胰腺炎入院的时间趋势和地理分布、巴西全国的致死率以及与社会指标和相关风险因素的潜在关系:2009年1月至2019年12月期间的数据来自巴西公共卫生系统登记处的回顾性数据。结果:在研究期间,每10万名居民中有64,607人患有慢性阻塞性肺病,其中有6,571人死于慢性阻塞性肺病:在研究期间,共检索到 64 609 例住院病例,大部分患者为男性(63.54%)。男女患者的住院率均下降了近一半(-54.68%)。在所有年龄组中,男性的 CP 率都较高。≥70岁患者的住院率降幅最大(-64%)。CP的院内致死率保持稳定(5-6%),男性和女性的致死率相似。≥70岁患者的致死率最高。CP致死率的最大增幅(+ 10%)出现在并入大都市的城市,这主要是由小城市(+ 124%)驱动的:城市和农村地区,尤其是北部、东北部和中西部地区,以及 70 岁以上人群的 CP 住院率均有所下降,但与南部地区的致死率无关。这表明巴西的环境和社会经济因素正在发生变化。
{"title":"Chronic Pancreatitis in a Large Developing Country: Temporal Trends of Over 64,000 Hospitalizations from 2009 to 2019.","authors":"Pedro Baldaque, Gabriela Coutinho, Jessica Pronestino de Lima Moreira, Ronir Raggio Luiz, Homero Soares Fogaça, Lucila Marieta Perrotta de Souza, Heitor Siffert Pereira de Souza","doi":"10.1007/s10620-024-08488-5","DOIUrl":"10.1007/s10620-024-08488-5","url":null,"abstract":"<p><strong>Background/objectives: </strong>Chronic pancreatitis (CP) is a progressive inflammatory disorder associated with marked morbidity and mortality and frequently requires hospitalization. This study aimed to investigate the time trends and geographical distribution of hospital admissions, the lethality rate of CP across Brazil, and the potential relationship with social indicators and associated risk factors.</p><p><strong>Methods: </strong>Data were retrospectively obtained from the Brazilian Public Health System Registry between January 2009 and December 2019. The prevalence and lethality rates of CP per 100,000 inhabitants in each municipality were estimated from hospitalizations to in-hospital deaths and classified by age, sex, and demographic features.</p><p><strong>Results: </strong>During the study period, 64,609 admissions were retrieved, and most of the patients were males (63.54%). Hospitalization decreased by nearly half (-54.68%) in both sexes. CP rates in males were higher in all age groups. The greatest reduction in admissions (- 64%) was also noted in patients ≥ 70y. CP In-hospital lethality remained stable (5-6%) and similar for males and females. Patients ≥ 70y showed the highest lethality. The greatest increase in CP lethality rates (+ 10%) was observed in municipalities integrated into metropolises, which was mainly driven by small-sized municipalities (+ 124%).</p><p><strong>Conclusions: </strong>CP hospitalizations decrease in both urban and rural areas, particularly in the North, Northeast, and Central-West regions, and in those above 70 years of age, but are not correlated with lethality rates in the South. This suggests ongoing changes in the environmental and socioeconomic factors in Brazil.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Obesity and Metabolic Syndrome on IBD Outcomes. 肥胖症和代谢综合征对肠道疾病结果的影响
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-12 DOI: 10.1007/s10620-024-08504-8
Maya Mahmoud, Wing-Kin Syn

Purpose of review: The recent surge in inflammatory bowel disease (IBD) cases has paralleled a significant rise in obesity and metabolic comorbidities rates. In this article, we explore the potential influence of obesity and associated metabolic comorbidities on disease progression, complications, treatment response, surgical outcomes, health economics, and the potential impact of obesity treatment on the course of IBD.

Findings: Contrary to visceral adiposity, obesity does not consistently result in an increased risk of IBD-related complications. Patients with IBD have a higher risk of acute arterial events, likely linked to systemic inflammation. Substantial evidence suggests that obesity has a negative impact on the response to IBD treatment, with this effect being most thoroughly studied in biologics and immunomodulators. The rates of overall complications and post-operative infections are higher in patients who are obese. There are limited but promising data regarding the impact of weight loss techniques, including exercise, medications, and bariatric interventions, on the outcomes in IBD. Both obesity and diabetes have adverse effects on the overall quality of life and place an increased financial burden on the IBD population. A growing body of evidence indicates a connection between obesity and associated metabolic comorbidities and negative outcomes in IBD, yet further efforts are required to fully understand this relationship.

综述的目的:近年来,炎症性肠病(IBD)病例激增的同时,肥胖和代谢合并症的发病率也显著上升。本文探讨了肥胖和相关代谢合并症对疾病进展、并发症、治疗反应、手术效果、卫生经济学的潜在影响,以及肥胖治疗对 IBD 病程的潜在影响:研究结果:与内脏脂肪过多相反,肥胖并不会持续增加 IBD 相关并发症的风险。IBD 患者发生急性动脉事件的风险较高,这可能与全身炎症有关。大量证据表明,肥胖会对 IBD 治疗的反应产生负面影响,生物制剂和免疫调节剂对这种影响的研究最为深入。肥胖患者的总体并发症和术后感染率较高。关于减肥技术(包括运动、药物和减肥干预)对 IBD 治疗效果的影响,目前的数据有限,但前景看好。肥胖和糖尿病都会对整体生活质量产生不利影响,并加重 IBD 患者的经济负担。越来越多的证据表明,肥胖和相关的代谢合并症与 IBD 的不良后果之间存在联系,但要充分了解这种关系还需要进一步的努力。
{"title":"Impact of Obesity and Metabolic Syndrome on IBD Outcomes.","authors":"Maya Mahmoud, Wing-Kin Syn","doi":"10.1007/s10620-024-08504-8","DOIUrl":"10.1007/s10620-024-08504-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>The recent surge in inflammatory bowel disease (IBD) cases has paralleled a significant rise in obesity and metabolic comorbidities rates. In this article, we explore the potential influence of obesity and associated metabolic comorbidities on disease progression, complications, treatment response, surgical outcomes, health economics, and the potential impact of obesity treatment on the course of IBD.</p><p><strong>Findings: </strong>Contrary to visceral adiposity, obesity does not consistently result in an increased risk of IBD-related complications. Patients with IBD have a higher risk of acute arterial events, likely linked to systemic inflammation. Substantial evidence suggests that obesity has a negative impact on the response to IBD treatment, with this effect being most thoroughly studied in biologics and immunomodulators. The rates of overall complications and post-operative infections are higher in patients who are obese. There are limited but promising data regarding the impact of weight loss techniques, including exercise, medications, and bariatric interventions, on the outcomes in IBD. Both obesity and diabetes have adverse effects on the overall quality of life and place an increased financial burden on the IBD population. A growing body of evidence indicates a connection between obesity and associated metabolic comorbidities and negative outcomes in IBD, yet further efforts are required to fully understand this relationship.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measures of Gut Inflammation in Patients with Inflammatory Bowel Disease: Are Blood-Based Biomarkers Sufficient? 炎症性肠病患者肠道炎症的测量方法:血液生物标记物是否足够?
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-07-29 DOI: 10.1007/s10620-024-08567-7
A Swaminathan, A S Day
{"title":"Measures of Gut Inflammation in Patients with Inflammatory Bowel Disease: Are Blood-Based Biomarkers Sufficient?","authors":"A Swaminathan, A S Day","doi":"10.1007/s10620-024-08567-7","DOIUrl":"10.1007/s10620-024-08567-7","url":null,"abstract":"","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-Specificity Phosphatase 4 Promotes Malignant Features in Colorectal Cancer Through Cyclic-AMP Response Element Binding Protein/Protein Kinase CAMP-Activated Catalytic Subunit Beta Activation. 双特异性磷酸酶 4 通过环-AMP 反应元件结合蛋白/蛋白激酶 CAMP 激活催化亚基 Beta 激活促进结直肠癌的恶性特征
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-01 DOI: 10.1007/s10620-024-08481-y
Wenju Pei, Wanbin Yin, Tao Yu, Xiaoyuan Zhang, Qi Zhang, Xiaowen Yang, Chunlei Shi, Wenzhi Shen, Gang Liu

Introduction: Previous studies have demonstrated that Dual-specificity phosphatase 4 (DUSP4) plays an important role in the progression of different tumor types. However, the role and mechanism of DUSP4 in colorectal cancer (CRC) remain unclear.

Aims: We investigate the role and mechanisms of DUSP4 in CRC.

Methods: Immunohistochemistry was used to investigate DUSP4 expression in CRC tissues. Cell proliferation, apoptosis and migration assays were used to validate DUSP4 function in vitro and in vivo. RNA-sequence assay was used to identify the target genes of DUSP4. Human phosphokinase array and inhibitor assays were used to explore the downstream signaling of DUSP4.

Results: DUSP4 expression was upregulated in CRC tissues relative to normal colorectal tissues, and DUSP4 expression showed a significant positive correlation with CRC stage. Consistently, we found that DUSP4 was highly expressed in colorectal cancer cells compared to normal cells. DUSP4 knockdown inhibits CRC cell proliferation, migration and promotes apoptosis. Furthermore, the ectopic expression of DUSP4 enhanced CRC cell proliferation, migration and diminished apoptosis in vitro and in vivo. Human phosphokinase array data showed that ectopic expression of DUSP4 promotes CREB activation. RNA-sequencing data showed that PRKACB acts as a downstream target gene of DUSP4/CREB and enhances CREB activation through PKA/cAMP signaling. In addition, xenograft model results demonstrated that DUSP4 promotes colorectal tumor progression via PRKACB/CREB activation in vivo.

Conclusion: These findings suggest that DUSP4 promotes CRC progression. Therefore, it may be a promising therapeutic target for CRC.

导言:以往的研究表明,双特异性磷酸酶4(DUSP4)在不同类型肿瘤的进展过程中发挥着重要作用。目的:研究 DUSP4 在结直肠癌(CRC)中的作用和机制:方法:采用免疫组化方法研究 DUSP4 在 CRC 组织中的表达。细胞增殖、凋亡和迁移试验用于验证 DUSP4 在体外和体内的功能。利用 RNA 序列分析鉴定 DUSP4 的靶基因。使用人类磷酸激酶阵列和抑制剂检测来探索 DUSP4 的下游信号转导:结果:与正常结直肠组织相比,DUSP4在CRC组织中表达上调,且DUSP4的表达与CRC分期呈显著正相关。同样,我们发现与正常细胞相比,DUSP4 在结直肠癌细胞中高表达。敲除 DUSP4 可抑制 CRC 细胞的增殖、迁移并促进细胞凋亡。此外,在体外和体内异位表达 DUSP4 能增强 CRC 细胞的增殖、迁移并减少细胞凋亡。人类磷酸激酶阵列数据显示,异位表达DUSP4可促进CREB活化。RNA测序数据显示,PRKACB是DUSP4/CREB的下游靶基因,通过PKA/cAMP信号增强CREB活化。此外,异种移植模型结果表明,DUSP4通过激活PRKACB/CREB促进体内结直肠肿瘤的进展:结论:这些研究结果表明,DUSP4 可促进 CRC 的进展。结论:这些研究结果表明,DUSP4 会促进 CRC 的进展,因此,它可能是 CRC 的一个有前景的治疗靶点。
{"title":"Dual-Specificity Phosphatase 4 Promotes Malignant Features in Colorectal Cancer Through Cyclic-AMP Response Element Binding Protein/Protein Kinase CAMP-Activated Catalytic Subunit Beta Activation.","authors":"Wenju Pei, Wanbin Yin, Tao Yu, Xiaoyuan Zhang, Qi Zhang, Xiaowen Yang, Chunlei Shi, Wenzhi Shen, Gang Liu","doi":"10.1007/s10620-024-08481-y","DOIUrl":"10.1007/s10620-024-08481-y","url":null,"abstract":"<p><strong>Introduction: </strong>Previous studies have demonstrated that Dual-specificity phosphatase 4 (DUSP4) plays an important role in the progression of different tumor types. However, the role and mechanism of DUSP4 in colorectal cancer (CRC) remain unclear.</p><p><strong>Aims: </strong>We investigate the role and mechanisms of DUSP4 in CRC.</p><p><strong>Methods: </strong>Immunohistochemistry was used to investigate DUSP4 expression in CRC tissues. Cell proliferation, apoptosis and migration assays were used to validate DUSP4 function in vitro and in vivo. RNA-sequence assay was used to identify the target genes of DUSP4. Human phosphokinase array and inhibitor assays were used to explore the downstream signaling of DUSP4.</p><p><strong>Results: </strong>DUSP4 expression was upregulated in CRC tissues relative to normal colorectal tissues, and DUSP4 expression showed a significant positive correlation with CRC stage. Consistently, we found that DUSP4 was highly expressed in colorectal cancer cells compared to normal cells. DUSP4 knockdown inhibits CRC cell proliferation, migration and promotes apoptosis. Furthermore, the ectopic expression of DUSP4 enhanced CRC cell proliferation, migration and diminished apoptosis in vitro and in vivo. Human phosphokinase array data showed that ectopic expression of DUSP4 promotes CREB activation. RNA-sequencing data showed that PRKACB acts as a downstream target gene of DUSP4/CREB and enhances CREB activation through PKA/cAMP signaling. In addition, xenograft model results demonstrated that DUSP4 promotes colorectal tumor progression via PRKACB/CREB activation in vivo.</p><p><strong>Conclusion: </strong>These findings suggest that DUSP4 promotes CRC progression. Therefore, it may be a promising therapeutic target for CRC.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Environmental Risk Factors in the Etiology of Inflammatory Bowel Diseases: A Multicenter Study. 环境风险因素在炎症性肠病病因学中的作用:一项多中心研究
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-05 DOI: 10.1007/s10620-024-08491-w
Cemile Cansu Alperen, Barıs Soydas, Ender Serin, Mustafa Erbayrak, Nurten Akyurek Savas, Gulhan Kanat Unler, Cenk Emre Meral, Ugur Toprak, Ahmet Sedat Boyacioglu, Ulku Dagli

Background: The increasing global incidence and prevalence of inflammatory bowel disease (IBD) necessitates an investigation into the potential influence of environmental risk factors on its origin.

Aim: This multicenter case-control study aimed to investigate potential environmental risk factors contributing to IBD development in Turkey.

Methods: The study included 156 Crohn's disease (CD), 277 ulcerative colitis (UC) patients, and 468 controls (matched for age and gender) from six hospitals' gastroenterology departments. Data collection relied on the International Organization of IBD's questionnaire on environmental factors. Each environmental factor was initially analyzed using univariate and subsequently multivariate logistic regression models.

Results: In the multivariate model, regular coffee consumption was associated with decreased odds for both CD (OR 0.28; 95% CI 0.14-0.55) and UC (OR 0.25; 95% CI 0.15-0.42). Stress was associated with UC (OR 3.27; 95% CI 1.76-6.10) and CD (OR 4.40; 95% CI 2.12-9.10) development. A history of childhood infectious diseases (gastroenteritis, upper respiratory tract infections, etc.) raised the odds for both CD (OR 9.45; 95% CI 2.51-35.6) and UC (OR 7.56; 95% CI 1.57-36.4). Conversely, consuming well/spring water (OR 0.22; 95% CI 0.10-0.50) and childhood antibiotic use (OR 0.41; 95% CI 0.18-0.93) showed a positive association against UC. Increased consumption of refined sugar and industrial food products emerged as risk factors for IBD. Smoking increased the risk for CD (OR 2.38; 95% CI 1.16-4.91), while ex-smoking increased the risk for UC (OR 3.16; 95% CI 1.19-8.37).

Conclusions: This study represents the first multicenter case-control study in Turkey examining the effects of environmental factors on IBD. It revealed that coffee consumption is positively associated, while stress and childhood infection-related diseases are risk factors. These findings, which are not supported by other studies, provide insight into the relationships between these factors and IBD.

背景:全球炎症性肠病(IBD)的发病率和流行率不断上升,因此有必要调查环境风险因素对其发病的潜在影响。目的:这项多中心病例对照研究旨在调查土耳其导致IBD发病的潜在环境风险因素:研究对象包括 156 名克罗恩病 (CD)、277 名溃疡性结肠炎 (UC) 患者和 468 名来自六家医院消化内科的对照组(年龄和性别匹配)。数据收集依赖于国际 IBD 组织的环境因素调查问卷。首先使用单变量逻辑回归模型对每个环境因素进行分析,然后使用多变量逻辑回归模型进行分析:在多变量模型中,经常喝咖啡与 CD(OR 0.28;95% CI 0.14-0.55)和 UC(OR 0.25;95% CI 0.15-0.42)的发病几率降低有关。压力与 UC(OR 3.27;95% CI 1.76-6.10)和 CD(OR 4.40;95% CI 2.12-9.10)的发病有关。有儿童传染病史(肠胃炎、上呼吸道感染等)会增加 CD(OR 9.45;95% CI 2.51-35.6)和 UC(OR 7.56;95% CI 1.57-36.4)的发病几率。相反,饮用井水/泉水(OR 0.22;95% CI 0.10-0.50)和儿童期使用抗生素(OR 0.41;95% CI 0.18-0.93)与 UC 呈正相关。精制糖和工业食品摄入量的增加是导致 IBD 的风险因素。吸烟会增加 CD 的风险(OR 2.38;95% CI 1.16-4.91),而曾经吸烟会增加 UC 的风险(OR 3.16;95% CI 1.19-8.37):本研究是土耳其第一项研究环境因素对IBD影响的多中心病例对照研究。研究显示,饮用咖啡与IBD呈正相关,而压力和儿童感染相关疾病则是风险因素。这些研究结果未得到其他研究的支持,但却有助于深入了解这些因素与 IBD 之间的关系。
{"title":"Role of Environmental Risk Factors in the Etiology of Inflammatory Bowel Diseases: A Multicenter Study.","authors":"Cemile Cansu Alperen, Barıs Soydas, Ender Serin, Mustafa Erbayrak, Nurten Akyurek Savas, Gulhan Kanat Unler, Cenk Emre Meral, Ugur Toprak, Ahmet Sedat Boyacioglu, Ulku Dagli","doi":"10.1007/s10620-024-08491-w","DOIUrl":"10.1007/s10620-024-08491-w","url":null,"abstract":"<p><strong>Background: </strong>The increasing global incidence and prevalence of inflammatory bowel disease (IBD) necessitates an investigation into the potential influence of environmental risk factors on its origin.</p><p><strong>Aim: </strong>This multicenter case-control study aimed to investigate potential environmental risk factors contributing to IBD development in Turkey.</p><p><strong>Methods: </strong>The study included 156 Crohn's disease (CD), 277 ulcerative colitis (UC) patients, and 468 controls (matched for age and gender) from six hospitals' gastroenterology departments. Data collection relied on the International Organization of IBD's questionnaire on environmental factors. Each environmental factor was initially analyzed using univariate and subsequently multivariate logistic regression models.</p><p><strong>Results: </strong>In the multivariate model, regular coffee consumption was associated with decreased odds for both CD (OR 0.28; 95% CI 0.14-0.55) and UC (OR 0.25; 95% CI 0.15-0.42). Stress was associated with UC (OR 3.27; 95% CI 1.76-6.10) and CD (OR 4.40; 95% CI 2.12-9.10) development. A history of childhood infectious diseases (gastroenteritis, upper respiratory tract infections, etc.) raised the odds for both CD (OR 9.45; 95% CI 2.51-35.6) and UC (OR 7.56; 95% CI 1.57-36.4). Conversely, consuming well/spring water (OR 0.22; 95% CI 0.10-0.50) and childhood antibiotic use (OR 0.41; 95% CI 0.18-0.93) showed a positive association against UC. Increased consumption of refined sugar and industrial food products emerged as risk factors for IBD. Smoking increased the risk for CD (OR 2.38; 95% CI 1.16-4.91), while ex-smoking increased the risk for UC (OR 3.16; 95% CI 1.19-8.37).</p><p><strong>Conclusions: </strong>This study represents the first multicenter case-control study in Turkey examining the effects of environmental factors on IBD. It revealed that coffee consumption is positively associated, while stress and childhood infection-related diseases are risk factors. These findings, which are not supported by other studies, provide insight into the relationships between these factors and IBD.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Esophageal Ulcer: Behçet's Disease or Tuberculosis? 食道溃疡:贝赫切特病还是肺结核?
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-12 DOI: 10.1007/s10620-024-08475-w
Juan Tan, Yingxuan Chen, Danfeng Sun
{"title":"Esophageal Ulcer: Behçet's Disease or Tuberculosis?","authors":"Juan Tan, Yingxuan Chen, Danfeng Sun","doi":"10.1007/s10620-024-08475-w","DOIUrl":"10.1007/s10620-024-08475-w","url":null,"abstract":"","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory Bowel Disease-Associated Arthritis Is Associated with Concomitant Autoimmune and Inflammatory Disorders. 炎症性肠病相关性关节炎与并发自身免疫性和炎症性疾病有关。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-20 DOI: 10.1007/s10620-024-08478-7
Madeline Alizadeh, Uni Wong, Bernadette C Siaton, Seema A Patil, Lauren George, Jean-Pierre Raufman, William H Scott, Erik C von Rosenvinge, Jacques Ravel, Raymond K Cross

Background: Extraintestinal Manifestations (EIMs) are a common and potentially debilitating complication of Inflammatory Bowel Diseases (IBD), sometimes requiring additional treatment beyond those used to control intestinal disease. IBD-associated arthritis (IAA), a form of spondyloarthritis, is associated with several factors including disease location, sex, and IBD type. However, much remains unknown about other clinical factors predicting development of EIMs. Our goal was to identify additional factors associated with IAA.

Methods: Participants in the LOCATION-IBD cohort were included in this analysis. We performed univariate and multivariate analysis of demographics, clinical data, and patient-reported outcomes data.

Results: The LOCATION-IBD cohort included 182 participants with (n = 53) and without (n = 110) joint EIMs and with joint pain of unclear etiology (n = 19). In a multivariate analysis comparing those with and without joint EIMs, female sex (OR = 2.5, p = 0.014), the presence of concomitant autoimmune and inflammatory disorders (OR = 2.5, p = 0.038), and Crohn's disease (OR = 2.9, p = 0.026) were associated with the presence of joint EIMs.

Conclusion: This analysis reveals patients with IAA are more likely to have concomitant autoimmune disorders. Further studies are needed to confirm this association, understand the mechanisms underlying the common pathogenesis of these concurrent disorders, and evaluate their impact on the treatment of IAA.

背景:肠道外表现(EIMs)是炎症性肠病(IBD)常见的并发症,有可能使人衰弱,有时除了用于控制肠道疾病的治疗外,还需要额外的治疗。IBD相关关节炎(IAA)是脊柱关节炎的一种形式,与疾病部位、性别和IBD类型等多种因素有关。然而,预测 EIMs 发展的其他临床因素仍有很多未知之处。我们的目标是找出与IAA相关的其他因素:本分析纳入了 LOCATION-IBD 队列中的参与者。我们对人口统计学、临床数据和患者报告的结果数据进行了单变量和多变量分析:LOCATION-IBD队列包括182名患有(n = 53)和未患有(n = 110)关节EIMs以及病因不明的关节疼痛(n = 19)的参与者。在对患有和未患有关节EIMs的患者进行的多变量分析中,女性(OR = 2.5,p = 0.014)、同时患有自身免疫性和炎症性疾病(OR = 2.5,p = 0.038)和克罗恩病(OR = 2.9,p = 0.026)与关节EIMs的存在有关:这项分析表明,IAA 患者更有可能同时患有自身免疫性疾病。需要进一步研究来证实这种关联,了解这些并发症的共同发病机制,并评估其对 IAA 治疗的影响。
{"title":"Inflammatory Bowel Disease-Associated Arthritis Is Associated with Concomitant Autoimmune and Inflammatory Disorders.","authors":"Madeline Alizadeh, Uni Wong, Bernadette C Siaton, Seema A Patil, Lauren George, Jean-Pierre Raufman, William H Scott, Erik C von Rosenvinge, Jacques Ravel, Raymond K Cross","doi":"10.1007/s10620-024-08478-7","DOIUrl":"10.1007/s10620-024-08478-7","url":null,"abstract":"<p><strong>Background: </strong>Extraintestinal Manifestations (EIMs) are a common and potentially debilitating complication of Inflammatory Bowel Diseases (IBD), sometimes requiring additional treatment beyond those used to control intestinal disease. IBD-associated arthritis (IAA), a form of spondyloarthritis, is associated with several factors including disease location, sex, and IBD type. However, much remains unknown about other clinical factors predicting development of EIMs. Our goal was to identify additional factors associated with IAA.</p><p><strong>Methods: </strong>Participants in the LOCATION-IBD cohort were included in this analysis. We performed univariate and multivariate analysis of demographics, clinical data, and patient-reported outcomes data.</p><p><strong>Results: </strong>The LOCATION-IBD cohort included 182 participants with (n = 53) and without (n = 110) joint EIMs and with joint pain of unclear etiology (n = 19). In a multivariate analysis comparing those with and without joint EIMs, female sex (OR = 2.5, p = 0.014), the presence of concomitant autoimmune and inflammatory disorders (OR = 2.5, p = 0.038), and Crohn's disease (OR = 2.9, p = 0.026) were associated with the presence of joint EIMs.</p><p><strong>Conclusion: </strong>This analysis reveals patients with IAA are more likely to have concomitant autoimmune disorders. Further studies are needed to confirm this association, understand the mechanisms underlying the common pathogenesis of these concurrent disorders, and evaluate their impact on the treatment of IAA.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparities in Advanced Therapy Initiation for Inflammatory Bowel Disease: Access Comes First. 炎症性肠病晚期治疗启动方面的差异:获得治疗是第一位的。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-07-29 DOI: 10.1007/s10620-024-08580-w
Jesse Siffledeen, Frank Hoentjen
{"title":"Disparities in Advanced Therapy Initiation for Inflammatory Bowel Disease: Access Comes First.","authors":"Jesse Siffledeen, Frank Hoentjen","doi":"10.1007/s10620-024-08580-w","DOIUrl":"10.1007/s10620-024-08580-w","url":null,"abstract":"","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Significance of Sarcopenia in Elderly Patients Undergoing Endoscopic Submucosal Dissection: A Systematic Review and Meta-analysis. 内镜粘膜下剥离术老年患者 "肌少症 "的临床意义:系统回顾与元分析》。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1007/s10620-024-08529-z
Yuanhao Su, Yongke Wu, Cheng Li, Yiyuan Zhao, Yunhao Li, Xing Jin, Zhidong Wang

Background and aims: As global life expectancy rises and gastrointestinal tumor incidence increases, more elderly patients are undergoing endoscopic submucosal dissection (ESD) for tumor treatment. The current situation highlights the importance of sarcopenia assessment before ESD. This systematic review and meta-analysis aim to assess sarcopenia's role in predicting post-ESD adverse outcomes in the elderly.

Methods: We conducted a systematic review and meta-analysis to investigate the impact of sarcopenia on the prognosis of elderly patients undergoing ESD treatment. A comprehensive search was conducted across three databases (PubMed, Embase, Web of Science). We were using NEWCASTLE-OTTAWA ASSESSMENT SCALE for risk of bias assessment. The data were synthesized using Review Manager 5.3.

Results: A total of 9 reports were identified, analyzing 7 indicators, with a combined sample size of 6044. Through a series of analyses, we have derived several highly credible research findings: the overall OR and 95% CI for gastric and colorectal post-ESD perforation between sarcopenia and nonsarcopenia groups were 1.34 [0.92, 1.97], for CTCAE grade > 2 was 2.65 [1.45, 4.82], for upper gastrointestinal post-ESD pneumonia were 1.97 [1.30, 2.99], and for gastric post-ESD mortality within 5 years were 2.96 [1.33, 6.58].

Conclusions: Sarcopenia is a risk factor for increased incidence of complications (CTCAE > 2) after undergoing gastric and colorectal ESD, increased pneumonia rates, and higher mortality rates within five years following gastric ESD treatment in elderly patients. However, sarcopenia does not lead to an increased perforation rate in elderly patients undergoing gastric and colorectal ESD treatments. Registration and protocol: The protocol for this study was registered on the Open Science Framework in 2024 https://doi.org/10.17605/OSF.IO/7B2CZ . We also conducted pre-registration on PROSPERO (CRD42024532547).

背景和目的:随着全球人均寿命的延长和胃肠道肿瘤发病率的增加,越来越多的老年患者接受内镜粘膜下剥离术(ESD)治疗肿瘤。目前的情况凸显了在进行 ESD 之前对肌肉疏松症进行评估的重要性。本系统综述和荟萃分析旨在评估肌肉疏松症在预测老年人ESD术后不良预后中的作用:我们进行了一项系统回顾和荟萃分析,以研究肌肉疏松症对接受 ESD 治疗的老年患者预后的影响。我们对三个数据库(PubMed、Embase、Web of Science)进行了全面检索。我们使用 NEWCASTLE-OTTAWA ASSESSMENT SCALE 评估偏倚风险。我们使用 Review Manager 5.3 对数据进行了综合:共发现 9 篇报告,分析了 7 项指标,样本量合计 6044 个。通过一系列分析,我们得出了几项可信度很高的研究结果:在肌肉疏松症组和非肌肉疏松症组之间,胃和结肠直肠ESD术后穿孔的总体OR值和95% CI值分别为1.34 [0.92,1.97],CTCAE>2级为2.65 [1.45,4.82],上消化道ESD后肺炎为1.97 [1.30,2.99],胃ESD后5年内死亡率为2.96 [1.33,6.58]:肌肉疏松症是导致老年患者接受胃部和结直肠ESD治疗后并发症(CTCAE>2)发生率增加、肺炎发生率增加以及胃部ESD治疗后五年内死亡率增加的风险因素。不过,在接受胃和结肠直肠ESD治疗的老年患者中,肌肉疏松症并不会导致穿孔率增加。注册和方案:本研究的方案已于 2024 年在开放科学框架(Open Science Framework)上注册 https://doi.org/10.17605/OSF.IO/7B2CZ 。我们还在 PROSPERO(CRD42024532547)上进行了预注册。
{"title":"Clinical Significance of Sarcopenia in Elderly Patients Undergoing Endoscopic Submucosal Dissection: A Systematic Review and Meta-analysis.","authors":"Yuanhao Su, Yongke Wu, Cheng Li, Yiyuan Zhao, Yunhao Li, Xing Jin, Zhidong Wang","doi":"10.1007/s10620-024-08529-z","DOIUrl":"10.1007/s10620-024-08529-z","url":null,"abstract":"<p><strong>Background and aims: </strong>As global life expectancy rises and gastrointestinal tumor incidence increases, more elderly patients are undergoing endoscopic submucosal dissection (ESD) for tumor treatment. The current situation highlights the importance of sarcopenia assessment before ESD. This systematic review and meta-analysis aim to assess sarcopenia's role in predicting post-ESD adverse outcomes in the elderly.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis to investigate the impact of sarcopenia on the prognosis of elderly patients undergoing ESD treatment. A comprehensive search was conducted across three databases (PubMed, Embase, Web of Science). We were using NEWCASTLE-OTTAWA ASSESSMENT SCALE for risk of bias assessment. The data were synthesized using Review Manager 5.3.</p><p><strong>Results: </strong>A total of 9 reports were identified, analyzing 7 indicators, with a combined sample size of 6044. Through a series of analyses, we have derived several highly credible research findings: the overall OR and 95% CI for gastric and colorectal post-ESD perforation between sarcopenia and nonsarcopenia groups were 1.34 [0.92, 1.97], for CTCAE grade > 2 was 2.65 [1.45, 4.82], for upper gastrointestinal post-ESD pneumonia were 1.97 [1.30, 2.99], and for gastric post-ESD mortality within 5 years were 2.96 [1.33, 6.58].</p><p><strong>Conclusions: </strong>Sarcopenia is a risk factor for increased incidence of complications (CTCAE > 2) after undergoing gastric and colorectal ESD, increased pneumonia rates, and higher mortality rates within five years following gastric ESD treatment in elderly patients. However, sarcopenia does not lead to an increased perforation rate in elderly patients undergoing gastric and colorectal ESD treatments. Registration and protocol: The protocol for this study was registered on the Open Science Framework in 2024 https://doi.org/10.17605/OSF.IO/7B2CZ . We also conducted pre-registration on PROSPERO (CRD42024532547).</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Digestive Diseases and Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1